TNThomas I. Neufeld

Thomas I. Neufeld

*This is an algorithmically generated author record based on publicly available information.

Thomas I. Neufeld has a total of 26 co-authors. Here are the top co-authors by number of shared publications:

  • Alessia Di Costanzo

    Department of Translational and Precision Medicine, Sapienza University of Rome, 00161 Rome, Italy

    1 shared publication
  • Anna Montali

    Departments of Translational and Precision Medicine (L.D’E., A.D.C., I.M., S.B., M.M., G.P., A.M., M.A.), Sapienza University of Rome, Italy

    1 shared publication
  • Antonio Nicolucci

    CORESEARCH Srl - Center for Outcomes Research and Clinical Epidemiology - Co. Ltd, Pescara, Italy (G.L., A.N.).

    1 shared publication
  • Carlo Catalano

    Department of Radiological Sciences, Oncology and Pathology, Policlinico Umberto I, Sapienza University, Rome, Italy

    1 shared publication
  • Chul Joo Kang

    Center for Cardiovascular Research, Division of Cardiology, Department of Medicine, Washington University School of Medicine

    1 shared publication
  • Davide Fierro

    Castelli Romani Hospital, Rome, Italy (D.F.).

    1 shared publication

Latest Publications

  • ANGPTL3 Deficiency and Risk of Hepatic Steatosis

    by Laura D’eRasmo, Michele Di Martino, Thomas Neufeld, Tyler J. Fraum, Chul Joo Kang, Kendall H. Burks, Alessia Di Costanzo, Ilenia Minicocci, Simone Bini, Marianna Maranghi, et al.

    BACKGROUND: ANGPTL3 (angiopoietin-like 3) is a therapeutic target for reducing plasma levels of triglycerides and low-density lipoprotein cholesterol. A recent trial with vupanorsen, an antisense oligonucleotide targeting hepatic production of ANGPTL3, reported a dose-dependent increase in hepatic fat. It is unclear whether this adverse effect is due to an on-target effect of inhibiting hepatic ANGPTL3. METHODS: We recruited participants with ANGPTL3 deficiency related to ANGPTL3 loss-of-function (LoF) mutations, along with wild-type (WT) participants from 2 previously characterized cohorts located in Campodimele, Italy, and St. Louis, MO. Magnetic resonance spectroscopy and magnetic resonance proton density fat fraction were performed to measure hepatic fat fraction and the distribution of extrahepatic fat. To estimate the causal relationship between ANGPTL3 and hepatic fat, we generated a genetic instrument of plasma ANGPTL3 levels as a surrogate for hepatic protein synthesis and performed Mendelian randomization analyses with hepatic fat in the UK Biobank study. RESULTS: We recruited participants with complete (n=6) or partial (n=32) ANGPTL3 deficiency related to ANGPTL3 LoF mutations, as well as WT participants (n=92) without LoF mutations. Participants with ANGPTL3 deficiency exhibited significantly lower total cholesterol (complete deficiency, 78.5 mg/dL; partial deficiency, 172 mg/dL; WT, 188 mg/dL; P P 0.05 for both deficiency groups compared with WT) or severity of hepatic steatosis as assessed by magnetic resonance imaging. In addition, ANGPTL3 deficiency did not alter the distribution of extrahepatic fat. Results from Mendelian randomization analyses in 36 703 participants from the UK Biobank demonstrated that genetically determined ANGPTL3 plasma protein levels were causally associated with low-density lipoprotein cholesterol ( P =1.7×10 -17 ) and triglycerides ( P =3.2×10 -18 ) but not with hepatic fat ( P =0.22). CONCLUSIONS: ANGPTL3 deficiency related to LoF mutations in ANGPTL3 , as well as genetically determined reduction of plasma ANGPTL3 levels, is not associated with hepatic steatosis. Therapeutic approaches to inhibit ANGPTL3 production in hepatocytes are not necessarily expected to result in the increased risk for hepatic steatosis that was observed with vupanorsen.


  • Open Access

    Differential Activation of a Mouse Estrogen Receptor β Isoform (mER β 2) with Endocrine-Disrupting Chemicals (EDCs)

    by Lauren J. Donoghue, Thomas I. Neufeld, Yin Li, Yukitomo Arao, Laurel A. Coons, Kenneth S. Korach

    Background: Endocrine-disrupting chemicals (EDCs) are suspected of altering estrogenic signaling through estrogen receptor (ER) α or β (mERβ1 in mice). Several EDC effects have been reported in animal studies and extrapolated to human studies. Unlike humans, rodents express a novel isoform of ERβ (mERβ2) with a modified ligand-binding domain sequence. EDC activity through this isoform remains uncharacterized. Objectives: We identified the expression pattern of mERβ2 in mouse tissues and assessed the estrogenic activity of EDCs through mERβ2. Methods: mERβ2 mRNA expression was measured in mouse tissues. HepG2 cells were used to assess the transactivation activity of mERβ isoforms with EDCs and ER co-activators. 293A cells transiently transfected with mER isoforms were used to detect EDC-mediated changes in endogenous ER target gene expression. Results: Expression of mERβ2 mRNA was detected in mouse reproductive tissues (ovary, testis, and prostate) and lung and colon tissues from both female and male mice. Five (E2, DES, DPN, BPAF, Coum, 1-BP) of 16 compounds tested by reporter assay had estrogenic activity through mERβ2. mERβ2 had a compound-specific negative effect on ERβ/ligand-mediated activity and ER target genes when co-expressed with mERβ1. mERβ2 recruited coactivators SRC2 or SRC3 in the presence of EDCs, but showed less recruitment than mERβ1. Conclusion: mERβ2 showed weaker estrogenic activity than mERβ1 in our in vitro system, and can dampen mERβ1 activity. In vivo models of EDC activity and ER-mediated toxicity should consider the role of mERβ2, as rodent tissue responses involving mERβ2 may not be reproduced in human biology. Citation: Donoghue LJ, Neufeld TI, Li Y, Arao Y, Coons LA, Korach KS. 2017. Differential activation of a mouse estrogen receptor β isoform (mERβ2) with endocrine-disrupting chemicals (EDCs). Environ Health Perspect 125:634–642; http://dx.doi.org/10.1289/EHP396